Information Provided By:
Fly News Breaks for August 18, 2017
TNXP
Aug 18, 2017 | 07:21 EDT
As previously reported, Roth Capital upgraded Tonix to Buy from Neutral with a price target of $6. Analyst Scott Henry believes Tonix's current valuation does not reflect the potential of the Tonmya program to treat PTSD and said the company has the cash runway to reach pivotal data readout in both first half 2018 and second half 2018. Additionally, the analyst said the AtEase trial has a reasonable chance for success with the higher 5 6 mg dose.
News For TNXP From the Last 2 Days
There are no results for your query TNXP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.